Sun, Dec 21, 2014, 12:30 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • bullaman@rocketmail.com bullaman Jun 4, 2013 2:36 PM Flag

    The math does not add up, here is why.

    Arry has many years more of trials, they have 85 Mill in cash, their debt is 95.6 million. The company offering Convertables to pay off debt 95.6 Million of it. That leave the Company with still 85 Million in cash, and they have many Trials. Where will the rest of money come from? I expect that they will dilute many more shares over the years because they have no partners. Diluting again will put a heavry drain in PPS. I remembered a Company called LEXG, the CEO diluted so many times that their PPS canno't eceed $2.30 because they are so heavily diluted and heavr market Cap with so many OS shares available. ARRY is becoming a diluting machine. After these Convertables, they still would need hunderds of Millions to carry out their Trials. I will not touck with a 40 foot pole anytime soon.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ARRY
4.86+0.06(+1.25%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
3M Company
NYSEFri, Dec 19, 2014 4:04 PM EST